Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.
BACKGROUND AND PURPOSE; The two phenylpiperidines, OSU6162 and ACR16, have been proposed as novel drugs for the treatment of brain disorders, including schizophrenia and Huntington's disease, because of their putative dopamine stabilizing effects. Here we evaluated the activities of these compounds in a range of assays for the D(2) dopamine receptor in vitro.


METHODS
The affinities of these compounds for the D(2) dopamine receptor were evaluated in competition with [(3) H]spiperone and [(3) H]NPA. Agonist activity of these compounds was evaluated in terms of their ability to stimulate [(35) S]GTPγS binding.


RESULTS
Both compounds had low affinities for inhibition of [(3) H]spiperone binding (pK(i) vs. [(3) H]spiperone, ACR16: <5, OSU6162: 5.36). Neither compound was able to stimulate [(35) S]GTPγS binding when assayed in the presence of Na(+) ions, but if the Na(+) ions were removed, both compounds were low-affinity, partial agonists (E(max) relative to dopamine: ACR16: 10.2%, OSU6162:54.3%). Schild analysis of the effects of OSU6162 to inhibit dopamine-stimulated [(35) S]GTPγS binding indicated Schild slopes of ∼0.9, suggesting little deviation from competitive inhibition. OSU6162 was, however, able to accelerate [(3) H]NPA dissociation from D(2) dopamine receptors, indicating some allosteric effects of this compound.


CONCLUSIONS
The two phenylpiperidines were low-affinity, low-efficacy partial agonists at the D(2) dopamine receptor in vitro, possibly exhibiting some allosteric effects. Comparing their in vitro and in vivo effects, the in vitro affinities were a reasonable guide to potencies in vivo. However, the lack of in vitro-in vivo correlation for agonist efficacy needs to be further addressed.


BACKGROUND
This article is part of a themed section on Analytical Receptor Pharmacology in Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2010.161.issue-6.
Kara
Elodie
E
School of Pharmacy, University of Reading, Reading, UK.
Lin
Hong
H
Svensson
Kjell
K
Johansson
Anette M
AM
Strange
Philip G
PG
D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D010880:Piperidines / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism*
D018491:Dopamine Agonists; D010880:Piperidines; D017448:Receptors, Dopamine D2; C109513:OSU 6162; C483720:pridopidine
Mol Endocrinol. 1992 Jun;6(6):920-6
1323056
Neuropharmacology. 2002 Oct;43(5):817-24
12384167
J Neurochem. 1993 Jan;60(1):372-5
8417160
J Biol Chem. 1987 Sep 5;262(25):12387-92
3040742
J Med Chem. 1994 Aug 19;37(17):2735-53
8064801
J Neurochem. 2001 Apr;77(2):493-504
11299312
Trends Pharmacol Sci. 2008 Jun;29(6):314-21
18471899
J Neurochem. 2010 Mar;112(6):1442-53
20050980
Pharmacol Rev. 2001 Mar;53(1):119-33
11171942
Br J Pharmacol. 2006 Oct;149(3):291-9
16921389
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Biochem Pharmacol. 2004 May 1;67(9):1657-65
15081865
Annu Rev Pharmacol Toxicol. 2001;41:237-60
11264457
J Neural Transm (Vienna). 2007 Sep;114(9):1143-6
17612788
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):677-85
15276693
J Neural Transm (Vienna). 2008 Jun;115(6):899-908
18351286
J Pharmacol Exp Ther. 2006 Aug;318(2):810-8
16648369
Neuropharmacology. 1999 Mar;38(3):331-8
10219971
Eur J Pharmacol. 2007 Feb 28;557(2-3):151-3
17157291
Nat Chem Biol. 2009 Sep;5(9):688-95
19648932
Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254
19883461